Gilead next earnings
WebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD - Get Rating) last announced its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.17. The business had revenue of $7.39 billion for the quarter, compared to analyst … Web1 day ago · GILEAD SCIENCES, INC. company earnings calendar and analyst expectations - Upcoming and past events Nasdaq: GILD Nasdaq. ... Next Year: Upcoming sector events for GILEAD SCIENCES, INC. 04/18/23 06:45am : JOHNSON & JOHNSON : Q1 2024 Earnings Release: 04/27/23 : ABBVIE INC. : Q1 2024 Earnings …
Gilead next earnings
Did you know?
WebAug 2, 2024 · Gilead , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.26 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 6.55%.... WebFeb 2, 2024 · Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2024 Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2024 Oncology Sales Increased Year-Over-Year by 71% for …
WebOn Feb 02, 2024, Gilead Sciences ( NASDAQ: GILD) reported Q4 2024 earnings per share (EPS) of $1.31, up 322.58% year over year. Total Gilead Sciences earnings for the quarter were $1.64 billion. In the same quarter last year, Gilead Sciences 's earnings per share (EPS) was $0.31. If you're new to stock investing, here's how to buy Gilead ... WebFeb 2, 2024 · Feb 2, 2024 4:30 PM ET. Webcast. Q4 2024 Earnings Release. Q4 2024 Presentation. Q4 2024 Supplementary Information. Q4 2024 Prepared Remarks. Q4 2024 Summary of Prepared Remarks. Q4 2024 Resource Book. Q4 2024 10-K.
Web2 days ago · Gilead reported oncology therapy sales of $2.1 billion in 2024, up 71%. Its lead oncology drug, personalized cell therapy Yescarta, is used to treat large B-cell lymphoma … WebApr 6, 2024 · Earnings for Gilead Sciences are expected to grow by 7.00% in the coming year, from $6.86 to $7.34 per share. Gilead Sciences has not formally confirmed its next …
WebFeb 2, 2024 · As of December 31, 2024, Gilead had $7.6 billion of cash, cash equivalents and marketable debt securities compared to $7.8 billion as of December 31, 2024. …
WebAug 2, 2024 · During the second quarter of 2024, Gilead generated $1.8 billion in operating cash flow. During the second quarter of 2024, Gilead made a $300 million collaboration upfront payment to Dragonfly, paid dividends of $920 million and repurchased $72 million of common stock. Product Sales Performance crypton supportWebOct 14, 2024 · For the most recent quarter, Gilead was expected to post earnings of $1.76 per share, but it reported $1.87 per share instead, representing a surprise of 6.25%. dut spring graduation 2022WebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter ... dut referencing styleWebGilead Sciences (GILD) reports earnings on 5/4/2024. Shares are down 1.5% since reporting last quarter. ... Shares are down 1.5% since reporting last quarter. The … dut student counselling youtubeWebApr 19, 2024 · For the most recent quarter, Gilead was expected to post earnings of $2.15 per share, but it reported $2.19 per share instead, representing a surprise of 1.86%. For the previous quarter, the ... dut sterling houseWebOct 29, 2024 · During the third quarter, adjusted Gilead earnings climbed 26% to $2.65 per share and crushed views for $1.76 a share. Sales were $7.42 billion, well above GILD stock analysts' call for $6.29 billion. dut registration feesWebFeb 22, 2024 · Earnings announcement* for GILD: Feb 02, 2024. Gilead Sciences, Inc. is expected* to report earnings on 02/02/2024 after market close. The report will be for the … dut school code